I'm LongbridgeAI, I can summarize articles.Anika Therapeutics reported Q2 FY26 net income of $3.31 million, reversing a prior-year loss, with revenue rising 16% to $32.61 million. Gross margin expanded by 14 percentage points to 65%, and adjusted EBITDA turned positive at $7.06 million. Both OEM and Commercial channel revenues grew double-digit percentages. The company is currently responding to an FDA deficiency letter regarding its Hyalofast product.
- Anika Therapeutics reported Q2 revenue of 32.61 million, up 16% year over year, as gross margin widened 14 percentage points to 65%. * Net income turned to 3.31 million, or USD 0.24 per diluted share, from a loss a year earlier. * Adjusted EBITDA (non-GAAP) rose to 7.06 million from a loss a year earlier. * OEM Channel revenue increased 14% to 18.71 million, while Commercial Channel revenue climbed 17% to 13.91 million. * Hyalofast remains under FDA PMA review, with the company responding to a deficiency letter received in January 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anika Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005012), on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here